PURE Bioscience (PURE Bioscience) Risk Assessment

View and export this data going back to 1996. Start your Free Trial

What is PURE Bioscience Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of PURE Bioscience is: No Data: Cannot be evaluated.

Competitive Comparison of PURE Bioscience's Risk Assessment

For the Household & Personal Products subindustry, PURE Bioscience's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PURE Bioscience's Risk Assessment Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, PURE Bioscience's Risk Assessment distribution charts can be found below:

* The bar in red indicates where PURE Bioscience's Risk Assessment falls into.

PURE Bioscience (OTCPK:PURE) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

PURE Bioscience Risk Assessment Related Terms

Thank you for viewing the detailed overview of PURE Bioscience's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

PURE Bioscience (PURE Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » PURE Bioscience Inc (OTCPK:PURE) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

771 Jamacha Road, No. 512, El Cajon, CA, USA, 92019

Website

https://www.purebio.com

PURE Bioscience Inc is engaged in developing and commercializing proprietary antimicrobial products. The company's technology platform is based on patented stabilized ionic silver, and its initial products contain silver dihydrogen citrate, or SDC. It offers PURE Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies and PURE Control as a direct food contact processing aid. It also manufactures and sells SDC-based products for end use, products preserved with SDC and SDC as a raw material ingredient for manufacturing use.

Executives

Robert F Bartlett	director	9669 HERMOSA AVENUE, RANCHO CUCAMONGA CA 91730
Bernard Blotner	director	9669 HERMOSA AVENUE, RANCHO CUCAMONGA CA 91730
Tom Y Lee	director	1807 SAN GABRIEL BLVD., SAN GABRIEL CA 91776
David Rendall	director	9669 HERMOSA AVENUE, RANCHO CUCAMONGA CA 91730
Kristin Taylor	director	13500 EVENING CREEK DRIVE N, SUITE 550, SAN DIEGO CA 92128
Dale Okuno	director	35 N. ARROYO PARKWAY, SUITE 1, PASADENA CA 91103
Ivan Chen	director	1725 GILLESPIE WAY, EL CAJON CA 92020
Thomas Richard Myers	officer: Chief Operating Officer	1725 GILLESPIE WAY, EL CAJON CA 92130
Henry R. Lambert	director, officer: Chief Executive Officer	1725 GILLESPIE WAY, EL CAJON CA 92020
Elisabeth Hagen	director	1725 GILLESPIE WAY, EL CAJON CA 92020
Janet Risi Field	director	9200 SOUTH DADELAND BOULEVARD, SUITE 800, MIAMI FL 33156
Franchise Brands, Llc	10 percent owner	325 BIC DRIVE, MILFORD CT 06461
Mark Stuart Elliott	officer: Vice President, Finance	1725 GILLESPIE WAY, EL CAJON CA 92020
William Otis	director	1725 GILLESPIE WAY, EL CAJON CA 92020
David M Theno	director	1725 GILLESPIE WAY, EL CAJON CA 92020